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EthiopiaAbstract Background: Group A Streptococcus (GAS) is an important cause of morbidity and
mortality among children and responsible for 20–30% of bacterial pharyngitis.
Objective: Determining prevalence, antimicrobial susceptibility pattern and clinical predictors of
GAS among children with pharyngitis.
Method: A cross sectional study was conducted on 355 children with pharyngitis attended in
Health Centers of Jimma town from May 8 to December 31, 2013. Demographic and clinical data
were collected by questionnaire. Throat swabs were collected and processed with the standard
microbiological techniques to isolate GAS. The disc diffusion method was used for antimicrobial
susceptibility testing. Descriptive statistics and multivariate logistic regression analysis were done
by SPSS version 20.
Results: Females accounted for 57.7% of 355 children with pharyngitis. Sixty-six percent of the
children were 5–9 years old giving mean ± SD age of 8.5 ± 2.7 years. The prevalence of GAS was
11.3%. All isolates of GAS were susceptible to penicillin and erythromycin. However, 52.5% were
resistant to tetracycline.Absence of cough, tonsillar swelling or exudate and temperature>38 Cwere
found to be independent predictors for GAS infection among children with pharyngitis (P< 0.05).
Conclusion: In this study the prevalence of GAS was relatively low. However, the seasonality of
GAS infection might underestimate the prevalence, so that large-scale prospective study in the entire
season and in various settings is required. In addition, the clinical variables that are predictor of GAS
pharyngitis can be considered for the diagnosis of GAS pharyngitis with further evaluation of its
reproducibility in different settings.
ª 2015 Egyptian Society of Ear, Nose, Throat and Allied Sciences. Production and hosting by Elsevier
B.V. All rights reserved.ed.
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Group A Streptococcus (GAS) is a Gram positive spherical
bacterium that causes different spectrum of human infections,
ranging from pharyngitis and pyoderma, to life threatening
immunological complications such as acute rheumatic fever
(ARF), rheumatic heart disease (RHD), post streptococcal
glomerulonephritis (PSGN), toxic shock syndrome (TSS) and
necrotizing fasciitis.1,2
Globally, it is estimated that about 600 million cases of
symptomatic GAS pharyngitis occur annually among people
aged over 4 years and over 550 million of these occur in less
developed countries. The greatest global burden of GAS disease
is due to RHD which follows GAS pharyngitis, where 15 mil-
lion cases and 349,000 deaths occur worldwide annually.
Ninety-ﬁve percent of the disease burden from RHD is in low
and middle income countries where it continues to have a sig-
niﬁcant impact on the health of children and young adults.
There are 2.4 million affected children between 5 and 14 years
of age in developing countries, 1 million of whom live in Sub-
Saharan Africa, making the continent the major ARF=RHD
hotspot.3–5
Ethiopia as one of the African countries shares the burden
of ARF. Accordingly, 50–64% of heart disease among chil-
dren was reported to be of rheumatic origin.6 Similarly, the
rate of RHD among cardiac admission in Ethio-Swedish
Children’s Hospital was 54.5%.7 It is also documented that
the prevalence of RHD among Ethiopian cardiac patients in
Addis Ababa city and Jimma town was 39.6% and 32.8%,
respectively.8,9
Despite the high burden of GAS pharyngitis and its severe
immunological sequelae, much is not done on epidemiology,
antimicrobial susceptibility pattern and clinical information
regarding the disease. Therefore, the aim of this study was to
determine the prevalence, antimicrobial susceptibility patternTable 1 The prevalence of GAS with respect to socio demographic
Southwest Ethiopia from May to December 2013.
Characteristics Cu
Ne
Sex Male 13
Female 18
Age in years 5–9 21
10–15 10
Residence Urban 29
Rural 21
Schoolinga status Yes 29
No 25
Educational status of the familyb Illiterate 45
Read & Write 16
1–4 grade 42
5–8 grade 79
9–12 grade 89
>12 grade 44
Familyb income per month (USD) 625 10
26–50 12
P50 86
Total 31
a Schooling: current schooling status of the children.
b Family: Mother, Father or Guardian.and clinical predictors of GAS among children with
pharyngitis.2. Materials and methods
2.1. Study participants
A cross sectional study was conducted on 355 children aged 5–
15 years with pharyngitis presenting at two Health Centers in
Jimma town from May to December 2013. Children who were
on antibiotic treatment or who had taken antibiotics within
7 days before sample collection were excluded from the study.
Patients’ demographic and clinical information were collected
using a structured questionnaire by trained health ofﬁcers.
2.2. Collection, transportation and processing of throat swab
Trained health ofﬁcers collected the throat samples from pos-
terior pharynx and tonsils using sterile cotton swabs.
Necessary care was taken not to swab the cheeks, tongues, lips
or other areas of the mouth. The swabs were placed immedi-
ately in Amies transport medium (Oxoid, England) and trans-
ported to Jimma University Microbiology Laboratory and
processed within 2 hours of collection.10,11
Then, the throat swabs were inoculated onto 5% sheep’s
blood agar plates and incubated for 24 h at 37 C in a candle
jar, which can provide an atmosphere of 5%CO2. Culture plates
negative for b-haemolytic colonies were incubated for addition-
al 24 hours to allow the growth of slow growers. Identiﬁcation
of GAS isolates was made based on the standard micro-
biological techniques which include b-haemolytic activity on
sheep’s blood agar, small colony characteristics, Gram positive
cocci , catalase production negative, 0.04-U bacitracin disc sus-
ceptibe and PYR positive (Hardy Diagnostics, USA) tests.10,12characteristics among children with pharyngitis in Jimma town,
lture result for GAS Total No. (%)
gative No. (%) Positive No. (%)
4 (89.3) 16 (10.7) 150 (42.3)
1 (88.3) 24 (11.7) 205 (57.7)
2 (90.2) 23 (9.8) 235 (66.2)
3 (85.8) 17 (14.2) 120 (33.8)
4 (89.1) 36 (10.9) 330 (93.0)
(84.0) 4 (16.0) 25 (7.0)
0 (87.9) 40 (12.1) 330 (93.0)
(100.0) 0 (0.0) 25 (7.0)
(84.9) 8 (15.1) 53 (14.9)
(100.0) 0 (0.0) 16 (4.5)
(95.5) 2 (4.5) 44 (12.4)
(87.8) 11 (12.2) 90 (25.4)
(89.0) 11 (11.0) 100 (28.2)
(84.6) 8 (15.4) 52 (14.6)
9 (85.2) 19 (14.8) 128 (36.1)
0 (93.8) 8 (6.2) 128 (36.1)
(86.9) 13 (13.1) 99 (27.9)
5 (88.7) 40 (11.3) 355 (100.0)
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Antimicrobial susceptibility testing was done by using the disc
diffusion method according to criteria set by Clinical
Laboratory and Standard Institute (CLSI) and European
Committee of Antimicrobial Susceptibility Testing
(EUCAST). The pure colony of GAS bacterial suspension
from brain heart infusion broth (BHI) was evenly spread onto
Muller Hinton agar supplemented with 5% sheep blood using
sterile cotton swab. Soon after, antibiotic discs were placed on
the inoculated plate and the plates were incubated at 37 C in a
candle jar overnight. The following antimicrobial discs with
respective concentration were used: penicillin (1 unit), ceftriax-
one (30 lg) and chloramphenicol (30 lg) all from [Becton
Deckinson BD, USA Company], amoxicillin (25 lg), ery-
thromycin (15 lg), clindamycin (2 lg), tetracycline (30 lg) all
from [Oxoid, England]. The antibiotic discs were selected
based on prescription pattern and recommendations from
CLSI and EUCAST. Zone of inhibition diameters were inter-
preted as sensitive, intermediate and resistant according to the
principles established by CLSI and EUCAST.13,14
2.4. Statistical analysis
Statistical analysis was done by SPSS version 20 statistical
software. Participants’ demographic and clinical characteristic
were described by using descriptive statistics. Bivariate and
multivariate logistic regression analysis were done to identify
the clinical predictors for GAS pharyngitis and P-value less
than 0.05 taken as statistically signiﬁcant at 95% conﬁdence
level.Table 2 The prevalence of GAS in relation to medical and treatmen
Ethiopia from May to December 2013.
Medical and treatment history
Sore throat episode in previous year Yes
No
Total
Recurrent sore throat episode in the previous year 1-Times
2-Times
3-Times
4-Times
5-Times
Total
Treatment measure for the episode taken Yes
No
Total
Place treatment measure taken Clinic
Traditional
Total
Uvulectomy Yes
No
Total
Duration of symptom for the current sore throat in days 1–2 days
3–4 days
P5 days
Total2.5. Ethical consideration
Ethical clearance was obtained from Jimma University Ethical
Review Board. Prior to recruitment of study participants, letter
of permission and written informed consent were secured from
the health facility managements and the parents=caregivers=
respectively. The purpose of the study was clearly described to
the study participants and conﬁdentiality was kept.3. Results
3.1. Socio-demographic characteristics and prevalence of GAS
A total of, 355 children between ages of 5 and 15 years with
pharyngitis were enrolled from May 8 to December 31, 2013.
Females accounted for 57.7% and urban residents were
93.0%. Sixty-six percent of the children were 5–9 years old
with mean ± SD age of 8.5 ± 2.7. Moreover, the average
family size of the target population was 4.6 with mean of 1.8
children less than 15 years per household (Table 1).
In this study, the overall prevalence of group A
Streptococcus (GAS) was 11.3% (40=355). The prevalence of
GAS in females was 11.7%, in children aged 10–15 years
14.2%, among rural residents 16% and in children with family
income 625 USD=month 14.8% (Table 1).
Sixty-three percent of children had an episode of sore
throat of which 27 (12.1%) were culture positive for GAS.
About 33.5% of study participant children experienced single
episode of sore throat in the previous year of which 14.7%
became culture positive for GAS. Similarly, 11.2% of thet history of children with pharyngitis in Jimma town, Southwest
Culture result for GAS Total No. (%)
Negative No. (%) Positive No. (%)
197 (87.9) 27 (12.1) 224 (63.1)
118 (90.1) 13 (9.9) 131 (36.9)
315 (88.7) 40 (11.3) 355 (100.0)
64 (85.3) 11 (14.7) 75 (33.5)
58 (93.5) 4 (6.5) 62 (27.7)
34 (87.2) 5 (12.8) 39 (17.4)
22 (95.7) 1 (4.3) 23 (10.3)
19 (76.0) 6 (24.0) 25 (11.2)
197 (87.9) 27 (12.1) 224 (100.0)
188 (87.4) 27 (12.6) 215 (96.0)
9 (100.0) 0 (0.0) 9 (4.0)
197 (87.9) 27 (12.1) 224 (100)
178 (87.7) 25 (12.3) 203 (94.4)
Healer 10 (83.3) 2 (16.7) 12 (5.6)
188 (87.4) 27 (12.6) 215 (100.0)
10 (90.9) 1 (9.1) 11 (3.1)
305 (88.7) 39 (11.3) 344 (96.9)
315 (88.7) 40 (11.3) 355 (100.0)
171 (87.7) 24 (12.3) 195 (54.9)
114 (90.5) 12 (9.5) 126 (35.5)
30 (88.2) 4 (11.8) 34 (9.6)
315 (88.7) 40 (11.3) 355 (100.0)
Table 3 Bivariate and multivariate logistic regression analysis of clinical predictors of GAS among children with pharyngitis in Jimma
town, Southwest Ethiopia from May to December 2013.
Clinical signs and symptoms Crude OR (95% CIa) P-value Adjusted ORb (95% CI) P-value
Cough Yes 1.00 1.00
No 3.608 (1.740–7.480) 0.001 3.778 (1.735–8.225) 0.001
Tonsillar swelling or exudate Yes 4.605 (1.757–12.074) 0.002 4.482 (1.631–12.314) 0.004
No 1.00 1.00
Body Temperature >38 C 3.275 (1.645–6.520) 0.001 3.479 (1.616–7.490) 0.001
638 C 1.00 1.00
Enlarged anterior cervical lymph node Yes 0.955 (0.494–1.845) 0.891 2.060 (0.983–4.316) 0.056
No 1.00 1.00
Drooling Yes 2.015 (0.821–4.947) 0.126 2.364 (0.864–6.471) 0.094
No 1.00 1.00
Rhinorrhea Yes 1.00 1.00
No 3.416 (0.797–14.631) 0.098 3.870 (0.826–18.139) 0.086
Dysphagia Yes 0.635 (0.284–1.415) 0.266
No 1.00
Hoarseness Yes 0.715 (0.327–1.561) 0.399
No 1.00
Abdominal pain Yes 1.00 0.446
No 0.762 (0.378–1.533)
Nausea Yes 1.169 (0.604–2.264) 0.643
No 1.00
Vomiting Yes 0.949 (0.477–1.891) 0.883
No 1.00
Otitis media Yes 1.107 (0.408–3.007) 0.842
No 1.00
Petechia on the palate Yes 1.073 (0.396–2.911) 0.889
No 1.00
Conjunctivitis Yes 1.00 0.318
No 0.619 (0.241–1.589)
a CI = Conﬁdence Interval.
b OR= Odds Ratio.
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24% were culture positive for GAS (Table 2).
3.2. Antimicrobial susceptibility pattern of GAS isolates
The antimicrobial drug susceptibility proﬁle showed that all
GAS isolates were susceptible to penicillin G, amoxicillin, ery-
thromycin, clindamycin, chloramphenicol and ceftriaxone.
However, more than 52% of those isolates were resistant to
tetracycline.
3.3. Clinical predictors for GAS pharyngitis in children
The bivariate logistic regression analysis was done to identify
clinical signs and symptom predictors for throat culture.
Accordingly, cough, tonsillar swelling or exudate, temperature
>38 C, drooling and rhinorrhea revealed statistically relevant
value (P< 0.25) to be considered for multivariate analysis. All
clinical predictors not showing P-value of <0.25 were removed
from the multivariate analysis. However, enlarged anterior cervi-
cal lymph node due to its clinical importance was included in the
multivariate analysis. Accordingly, the three clinical variables
including absence of cough [AOR 3.77, 95% CI 1.73–8.22,
P= 0.001], tonsillar swelling or exudate [AOR 4.48, 95% CI
1.63–12.31, P= 0.004] and temperature >38 C [AOR 3.47,
95%CI 1.61–7.49,P= 0.001] were found to be independent pre-
dictors for GAS pharyngitis in children (Table 3).4. Discussion
Group A Streptococcus (GAS) is the most common bacterial
cause of acute pharyngitis, responsible for 20–30% of sore
throat in children.15 The overall prevalence of 11.3% GAS
detected in our study was comparable with 11% reported in
Turkey,16 12% in Brazil17 and 9.7% among healthy school
children in Ethiopia.18 But, it was much higher than the preva-
lence of 2.8%, 4.1% and 7.9%, in India,19 Taiwan20 and
Indonesia21 respectively.
On the other hand, the 11.3% prevalence of GAS in our
study was much lower than 40.6% reported in Ethiopia.6
This low prevalence of GAS in the current study may be due
to a difference in seasons where the previous study in
Ethiopia was conducted from February to May when the car-
riage rate and infection of GAS reached the maximum.
Moreover, civil war during 1992 in Ethiopia may have con-
tributed to an inﬂux of people to the big cities causing crowd-
ing and lower standards of living which might be the reason for
observed high prevalence of GAS in the former study.6 In
addition to this, the low prevalence rate in our study is prob-
ably due to the trends of over prescription of antibiotics in
health facilities as it was demonstrated in our data where
100% of children with pharyngitis received either amoxicillin
or penicillin. Such indiscriminate use of antibiotics might con-
tribute for the low carriage rate of GAS in the community.
Similarly, 11.3% prevalence of GAS in our study was lower
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USA26 where average prevalence of 17–58% was reported.
Such variation may be due to differences in methodology, sea-
sons of sample collection and geographical variation of study
settings.
In this study, all GAS isolates were susceptible to penicillin,
amoxicillin, erythromycin, clindamycin, chloramphenicol and
ceftriaxone, which go in agreement with previous studies in
Ethiopia6,18 where no b-lactams and macrolides drug resistant
was reported. These ﬁndings indicated that b-lactams and
macrolides remain as the drug of choice for the treatment of
GAS infection. It is known that erythromycin and clindamycin
are usually used as an alternative treatment for patients aller-
gic to penicillin. Fortunately in this study, no single isolate of
GAS became resistant to erythromycin and clindamycin which
was in agreement with ﬁndings elsewhere in Ethiopia,6,18
Egypt22 and Brazil.27 However, various levels of resistance to
erythromycin and clindamycin were reported in Turkey,16
Tunisia28 and China.29 In the present study, 52.5% GAS iso-
lates were resistant to tetracycline which was comparable with
68% reported in Ethiopia6 and 50% in Brazil,27 but much low-
er than 70% and 94% resistance rates documented in Tunisia28
and China29 respectively.
According to multivariate logistic regression analysis,
absence of cough, presence of tonsillar swelling or exudate
and body temperature >38(P< 0.05) were found to be inde-
pendent predictors for GAS infection among children with
pharyngitis. Similar ﬁndings were revealed in Canada,30
USA31–33 and Yemen.24 However, it is important to know that
the clinical variables that are predictor for GAS infection may
vary with different GAS strains, geographic area and immuni-
ty proﬁle of the study population.22
5. Conclusion
In this study the prevalence of GAS was relatively low.
However, the seasonality of GAS infection might underesti-
mate the prevalence, so that large-scale prospective study in
the entire season and in various settings is required to under-
stand the actual burden of infection. In our study, all GAS iso-
lates remained susceptible to penicillins and macrolides
indicating that those are still the drug of choice for the treat-
ment of GAS infection in that locality. Furthermore, the clin-
ical variables that are predictor of GAS pharyngitis can be
considered for the diagnosis of GAS pharyngitis with further
evaluation of its reproducibility in different settings.
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